Landos Biopharma, Inc.

General Information

We are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. We aim to inhibit the inflammatory responses by changing the metabolic processes in target cells.

Through our proprietary AI-based precision medicine platform – our LANCE platform – we have identified seven novel immunometabolic targets and product candidates to date across 14 indications: ulcerative colitis (UC); Crohn’s disease (CD); lupus; rheumatoid arthritis; NASH (nonalcoholic steatohepatitis); multiple sclerosis (MS); Alzheimer’s disease; asthma; psoriasis; atopic dermatitis; eosinophilic esophagitis (EoE); chronic obstructive pulmonary disease (COPD); diabetic nephropathy, and Type 1 diabetes. 

Our lead product candidate, BT-11, is a gut-restricted oral therapeutic that is the first candidate designed to engage the novel target, lanthionine synthetase C-like protein 2, or LANCL2, a membrane receptor shown to modulate immunological mechanisms associated with autoimmune diseases such as UC or CD. Approximately 2 million Americans suffer from UC or CD, and the treatment of these two diseases in the United States accounts for an aggregate annual market size of up to $17 billion. There are currently no approved treatments that target LANCL2. BT-11 is designed to act locally in the gastrointestinal tract to treat inflammatory bowel disease, or IBD. We have designed BT-11 to overcome limitations of existing therapies, including with respect to side effect profiles, route of administration (injectables) and sustained efficacy.

Industry: Pharmaceuticals
Founded: 2017
Contact Information
Address 1800 Kraft Drive, Suite 216 Blacksburg, VA 24060
Phone Number (540) 218-2232
Web Address
View Prospectus: Landos Biopharma, Inc.
Financial Information
Market Cap $626.56mil
Revenues $0 mil (last 12 months)
Net Income $-23.3 mil (last 12 months)
IPO Profile
Symbol LABP
Exchange NASDAQ
Shares (millions): 6.3
Price range $16.00 - $16.00
Est. $ Volume $100.0 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ SVB Leerink
CO-Managers Raymond James
Expected To Trade: 2/4/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change